Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European ...

"It affected everything. It made being a dad so difficult - especially as my children are both younger than four." ...

Ustekinumab is effective and safe and shows a high rate of clinical remission and treatment persistence in patients with ulcerative colitis.

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

This month, the company received FDA approval for a subcutaneous induction regimen of Tremfya (guselkumab) to treat adults ...

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European ...

A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, ...

Phase 3 data showed comparable safety and efficacy of subcutaneous and intravenous induction regimens of guselkumab for ...

The Food and Drug Administration (FDA) has expanded the approval of Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) to include a ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...